Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin for Prevention of Delayed Graft Function After Kidney Transplant
NCT00248040Phase 2Completed
- Sponsor
- Dompé
- Start
- Oct 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of reparixin in delayed graft function (DGF) (3 arms), sponsored by Dompé. Primary endpoint: Creatinine Clearance in the Immediate Post-transplant Period. Started Oct 2005; status: completed.
02
Drugs
reparixin
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT00248040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248040.